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Abstract
Background: Utility of visual impairment caused by amblyopia is important for the cost-effectiveness of screening
for amblyopia (lazy eye, prevalence 3–3.5 %). We previously measured decrease of utility in 35-year-old persons with
unilateral persistent amblyopia. The current observational case–control study aimed to measure loss of utility in
patients with amblyopia with recent decrease of vision in their better eye. As these patients are rare, the sample
was supplemented by patients with bilateral age-related macular degeneration with similar decrease of vision.
Methods: From our out-patient department, two groups of patients with recent deterioration to bilateral visual
acuity less than Snellen 0.5 (bilateral visual impairment, BVI) were recruited, with either persistent amblyopia and
age-related macular degeneration (AMB + AMD), or with bilateral age-related macular degeneration (BAMD).
To measure utility, the time trade-off method and the standard gamble method were applied through interviews.
Correlations were sought between utility values and visual acuity, age and Visual Function Questionnaire-25 scores.
Results: Seventeen AMB + AMD patients (mean age 72.9 years), and 63 BAMD patients (mean age 79.6 years) were
included in the study. Among AMB + AMD, 80 % were willing to trade lifetime in exchange for cure. The overall mean
time trade-off utility was 0.925. Among BAMD, 75 % were willing to trade, utility was 0.917. Among AMB + AMD, 38 %
accepted risk of death in exchange for cure, overall mean standard gamble utility was 0.999. Among BAMD, 49 %
accepted risk of death, utility was 0.998. Utility was not related to visual acuity but it was to age (p = 0.02).
Conclusion: Elderly patients with BVI, caused by persistent amblyopia and age-related macular degeneration (AMD) or
by bilateral AMD, had an approximately 8 % loss of TTO utility. Notably, the 8 % loss in elderly with BVI differs little from
the 3.7 % loss we found previously in 35-year-old persons with unilateral amblyopia with good vision in the other eye.
The moderate impact of BVI in senescence could be explained by adaptation, comorbidity, avoidance of risk and a
changed percept of cure.
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Background
Amblyopia (lazy eye) is not congenital, but results from
strabismus (squint) or from anisometropia (unequal refract-
ive power of the eyes), or, rarely, from deprivation of the
eye, caused by congenital cataract, for instance. It has a
prevalence of 3–3.5 %, depending on population and cri-
teria [1]. In developed countries, most children with ambly-
opia are detected by pre-school screening by measurement
of the visual acuity at age four or five. Amblyopia can be
treated before the age of seven. If insufficiently treated or
unresponsive to treatment, the eye with persistent ambly-
opia retains a Snellen visual acuity (VA) of less than 0.5 and
patients will be unable to read with that eye during the rest
of their life.
The cost-effectiveness of screening programmes for
amblyopia has been the subject of several reports [2, 3]. In
a report by Carlton et al. [2] the cost-effectiveness of vision
screening up to the age of 4–5 years was examined. They
concluded that the cost-effectiveness of screening for
amblyopia depends primarily on the long-term utility
* Correspondence: Simonsz@compuserve.com
1Department of Ophthalmology, Erasmus MC, University Medical Center
Rotterdam, PO Box 2040NL-3000 CA Rotterdam, The Netherlands
Full list of author information is available at the end of the article
© 2016 van de Graaf et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
van de Graaf et al. BMC Ophthalmology  (2016) 16:56 
DOI 10.1186/s12886-016-0234-0
effects of unilateral vision loss caused by persistent ambly-
opia and that there is currently no evidence of loss in utility
that would render any screening to be cost-effective.
In a previous study, we examined the decrease in quality
of life in a historic cohort of adults with amblyopia by a
questionnaire [4]. We subsequently measured the loss of
utility due to unilateral persistent amblyopia in the same
historic cohort of adult persons with unilateral persistent
amblyopia, 35–40 years old, who had, 30–35 years previ-
ously, been treated for amblyopia in Waterland, a rural
region north of Amsterdam [5]. This historic cohort
formed an almost random sample, as almost all children
with amblyopia and/or strabismus were referred and
treated by the only ophthalmologist and only orthoptist in
Waterland at the time. Almost half of them could be
contacted 30–35 years later. Seventy percent of these per-
sons (N = 135) were willing to trade lifetime in exchange
for cure, i.e. perfect vision, measured by the Time Trade-
Off (TTO) method. They had, on average, a utility of
0.963, in other words, a loss of utility of 3.7 %. The loss of
utility correlated with the current visual acuity of the
amblyopic eye [5].
Occasionally, persons with unilateral persistent ambly-
opia also lose the function of their better eye, usually at an
older age. Among 6-years-olds with persistent amblyopia,
the period of time at the end of their life with bilateral
visual impairment (BVI) defined in that in the current
study as Snellen VA of < 0.5 in both eyes is, on average,
fifteen-and-a-half months against eight months in healthy
six-years-olds, according to our longitudinal study per-
formed in a population cohort of elderly [6].
In the current study we measured the utility in the
patients with unilateral persistent amblyopia (either de-
tected too late, insufficiently treated by glasses or patch-
ing, or unresponsive to treatment) who recently suffered a
loss of vision in the better eye due to age-related macular
degeneration (AMB +AMD). As these patients are rare,
the sample was supplemented by patients who had bilat-
eral age-related macular degeneration (BAMD) and also
recently suffered a loss of vision in the better eye.
Methods
Patients from the ophthalmology out-patient clinic,
Erasmus MC, Rotterdam were recruited from Autumn
2009 till Spring 2011 to form two groups of consecu-
tive patients. Included in the study were those with
amblyopia with a VA of less than 0.5 (Snellen) with a
recent reduction of vision in the better eye due to
AMD, the AMB + AMD group, and those with existing
AMD in one eye and recent reduction of vision in the
better eye due to AMD (both eyes Snellen VA < 0.5), the
BAMD group. Data were collected by patients-interviews
for approximately thirty minutes by the first author.
Patients who could not be interviewed because of illness
or inability to speak Dutch were excluded. The decrease
in VA had occurred within six months before the date of
interviewing the patients. As the patient’s eyes were treated
with injections of bevacuzimab for AMD, sometimes the
VA of the deteriorated eye had improved before the inter-
view. Diagnostic VA measurements had been performed by
optometrists, ophthalmologists and residents, and were
taken from the patient’s medical record for this study.
Utility is the preference or value (ranging from 1.0,
perfect health, to 0.0, death) the patient assigns to his
present health state including the disability he/she expe-
riences, like bilateral visual impairment in this study.
Direct patient’s preferences about the health state of BVI
were obtained by the methods of Time Trade-Off (TTO)
and Standard Gamble (SG). Both methods were based
on the same search procedure and forced search alterna-
tives as previously used [5].
TTO utilities were elicited by posing patients the ques-
tion: “Suppose there is a hypothetical medicine that re-
stores perfect vision in both eyes, but it would shorten
your remaining lifetime; would you give up … (lifetime-al-
ternative) in exchange for perfect vision”. Forced TTO
search alternatives were “no time”, “1 day”, “1 week”,
“1 month”, “3 months”, “6 months”, “1 year”, “2 years” and
“5 years”. SG utilities were elicited by posing patients the
question: “Suppose there is a hypothetical surgery that
restores perfect vision in both eyes, but here is an immedi-
ate risk of death; would you accept such risk of …(risk-al-
ternative) in exchange for perfect vision”. Forced SG
search alternatives were “no risk”, “risk of 1:20,000”,
“1:10,000”, “1:1,000”, “1:200”, “1:100” and “1:50”.
The patients were in addition asked to choose, out of
three, the most troubling aspect of the affected visual
eye function: Blurred vision in the worse eye, blurred
vision in the center of the visual field of the better eye
or lack of depth vision. The measured utility values were
compared with the VA in the better eye to ascertain
whether the utility values were associated to VA.
Finally, all patients filled out the National Eye Institute
Visual Function Questionnaire-25 with supplement (VFQ-
25) which is a general vision quality-of-life instrument [7].
Statistics were performed in Excel 2003 and SAS 9.2,
the significance test of the group-difference and the cor-
relation between the VFQ-25 scores and utility value in
SPSS (version 13).
Results
Study population
Patients were recruited from Autumn 2009 till Spring
2011 from the ophthalmology out-patient clinic, at the
Erasmus Medical Center. The 17 AMB+AMD patients
were 35 % male and had a mean age of 72.9 ± 10.4 and
median age of 76 at the time of the interview. The 63
BAMD patients were 38 % male and had a mean age of
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79.6 ± 7.2 and median age of 81 at the time of the inter-
view. The age difference, 72.9 for the AMB+AMD against
79.6 for BAMD, was significant: P = 0.031 (two-tailed) on
the non-parametric Mann–Whitney test. At the beginning
of the interview the patients were asked how long they ex-
pected to live. The self-estimated life expectancy for the
AMB+AMD-group was 82.1 and for the BAMD-group
89.3.
The 80 patients were interviewed, in 13 cases face-by-
face immediately after or before their ophthalmologic
treatment at the Erasmus Medical Center or during a
visit at their home and in 67 by phone, within a week
after their ophthalmologic consult at the Erasmus Med-
ical Center, taking approximately 30 min. In the AMB +
AMD group, one patient was excluded because of ill-
ness. No patient refused the interview. In the BAMD
group, three patients were excluded, two because of
illness and one because of the inability to speak Dutch.
The distribution of the VA of the recently impaired
eye at the time of the interview from all 80 patients is
shown in Fig. 1 (left bars). The patients are listed by age,
from 56 to 96 years, at the time of the interview.
Utility values
TTO utility value was equal to: 1 - traded lifetime / self-
estimated life expectancy. Mean TTO utility for AMB +
AMDs was 0.925, and for BAMDs 0.917 (Table 1).
Mean traded lifetime and TTO mean utility values were
approximately the same for both groups (averaged over all
patients per group) (Table 1). Logarithmic mean TTO
utility was higher for both groups (averaged only over
patients per group who were willing to trade lifetime)
(Table 1). The standard deviation given does not reflect
true variation, as the distribution is skewed and the utility
value cannot exceed 1.0. Significant correlation was found
for all patients (N = 80) between TTO utility and age
Fig. 1 Distribution of the VA of the recently deteriorated eye (left bars) and TTO utility values (right bars) from all patients, listed by age. The 80
patients are listed from age 56 (bottom) to age 96 (top) on the ordinate. The centre column represents the age of the youngest patient of each
five-year age group. In other words, the youngest patients in the sixty to sixty-four year age group is marked sixty. The open bars represent the
AMB + AMD patients, the black bars represent the BAMD patients. Left bars represent Snellen VA, from worst (right) to best (left). Two patients
with unilateral persistent amblyopia were later found to have VA of 0.9 in the amblyopic eye. Distribution of TTO utility from all patients is given
at the right. The value at the right side of the bar represents the TTO utility, so the length of the bar depicts the difference between 1 and the
TTO utility, which indicates the loss of TTO utility. No bar means that the patient was not willing to trade any remaining lifetime for cure
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(linear regression with bootstrap method, p < 0.001). Most
of the oldest persons were unwilling to give up any life-
time. The TTO utility values from all 80 patients are also
represented in Fig. 1 (right bars). Figure 1 shows that
older patients were less willing to give up lifetime (top
right). There was no significant relation between TTO
utility and the patients’ VA (left bars), but there was be-
tween TTO utility and age for the BAMD-group.
SG utility value was equal to: (1 - accepted risk of
death). Of the AMB + AMDs, only 38 % accepted risk of
death and of the BAMDs, 49 % accepted such risk. The
mean risk of death they accepted was 1 in 10,000 and 1
in 50,000, respectively (Table 1). The risk of death alter-
natives that were accepted ranged from 1 in 50 (two
patients: aged over 80 years, each with BAMD) to 1 in
20,000. Mean SG utility for the AMB +AMD-group was
0.999, and for the BAMD-group 0.998. Logarithmic
mean SG utility, averaged over the patients per group
only who accepted risk of death, was 0.999 for both
groups.
The inclusion criterion of a decrease in Snellen VA to
less than 0.5 could not be upheld in one patient who
had Snellen VA of 0.5. Another patient had a known
amblyopia with Snellen VA 0.8 when he entered into the
study. Later, after full correction with glasses, they were
both found to have improved to Snellen VA of 0.9 in the
amblyopic eye. Some patients had had an abrupt decrease
of VA (Fig. 2a) whereas others had a slow decrease. It was
difficult to ascertain the exact date of the decrease of VA:
There was a delay between the occurrence of acuity de-
crease and the diagnosis by the ophthalmologist, in
addition to the waiting time for the appointment with the
general practitioner and for that with the ophthalmologist
(Fig. 2b). Finally, as the patient’s eyes were injected
with bevacuzimab for AMD progression, the VA of
the deteriorated eye had improved in six patients
around or after the time of the interview (Fig. 2c).
All patients chose, out of three possibilities, the visual
function that disturbed them most. Patients of both
groups found blurred vision in the center of the visual
field of the better eye the most troubling disturbance: 77
% of the AMB +AMD and 52 % of the BAMD patients.
Blurred vision in the worse eye was the second most
troubling visual function for the AMB +AMDs (17 %)
and the BAMDs (42 %). Metamorphopsia, i.e. a wrinkled
image caused by AMD was mentioned by some patients
during the interview.
Comparison with VFQ-25
The questions of the VFQ-25 associated with patients’ low
quality of life concerned reading of normal print of books
and newspapers, small print on groceries and subtitles of
television programs, driving a car, writing, and hobbies
like embroidery and stitching work. The lifetime which
the patients were willing to trade had only a modest cor-
relation with the VFQ-25 A2 scale on vision health: P
= .077 with Spearman correlation -.240. It was not corre-
lated with the VFQ-25 A1 scale on general health, al-
though co-morbidities like diabetes or heart failure were
mentioned during the patient-interviews. Visual aids were
used in order to read: most patients used hand-held mag-
nifiers, some used plate magnifiers for newspapers and
some used telescope glasses for subtitles.
Discussion
Elderly patients with BVI, either caused by persistent am-
blyopia and AMD, or caused by bilateral AMD had an
overall mean TTO utility value of approximately 0.92, in
other words approximately 8 % loss of TTO utility. Previ-
ous studies of utility of BVI found considerably lower TTO
values, of 0.73 or less [8, 9], but these authors applied either
indirect methods (indexed health states evaluated by prede-
termined search alternatives) or clinicians’ and community
members’ derived preferences. In view of the moderate loss
of utility we found, together with the rare occurrence of
BVI in patients with amblyopia, it seems that the impact of
loss of function of the better eye on the cost-effectiveness
of screening for amblyopia is minor. The 8 % utility loss in
elderly with BVI we found in this study differs little from
the utility loss of 3.7 % we found previously in young adult
persons with unilateral persistent amblyopia with good
vision in the other eye [5]. That condition occurs much
more frequently, approximately 0.9 % of the population in
the RAMSES birth cohort study [1] and therefore its im-
pact on the cost-effectiveness of screening for amblyopia is
large.
A similar fraction of the AMB+AMD and the BAMD
patients, viz. 80 and 75 %, respectively, was willing to trade
lifetime: on average sixteen months vs. fourteen months.
Table 1 TTO and SG results from the patient groups
Time trade-off
Traded lifetime Utility value
Groups N % Mean Mean Sd Log. Mean
AMB + AMD 12 80 16 months 0.925 0.09 0.946
BAMD 41 75 14 months 0.917 0.11 0.943
Standard gamble
Accepted death risk Utility value
Groups N % Mean Mean Sd Log. Mean
AMB + AMD 6 38 0-1:10,000 0.999 0.0004 0.999
BAMD 27 49 0-1:50,000 0.998 0.004 0.999
Note: Mean traded lifetime, mean accepted death risk, mean Time Trade-Off
utility value and mean Standard Gamble utility value are averaged over all
patients per group. “AMB + AMD” denotes amblyopia and age-related macular
degeneration, “BAMD” bilateral age-related macular degeneration, “Sd”
standard deviation, “Log. Mean” logarithmic mean
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Fig. 2 TTO utility value (diamond), SG utility value (square) and consecutive visual acuity of both eyes set against time in months as illustrated by
three patients. The abscissa represents time VA measured in months. Scale of TTO utility, SG utility and visual acuity are represented by the
ordinate. It runs from 0.0 to 1.0, signifying either Snellen VA, measured TTO utility or measured SG utility. Open diamonds and open squares
represent TTO and SG utility at the time of the interview. VA of the right eye is represented by filled-in circles, VA of the left eye by filled-in
squares, connected by lines. VA was measured in the months preceding the interview and/or after the interview. The association between visual
acuity and the decrease in visual acuity on the one hand, and measured utility on the other hand, is very weak
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The average age was 72.9 years in the AMB+AMD group
and 79.6 years in the BAMD group. The difference in age
between the two groups (significance p = 0.031; Mann–
Whitney test) was to be expected as BVI occurs earlier in
persons with unilateral persistent amblyopia than in healthy
persons [6]. Both groups estimated their remaining lifespan
at approx. 10 years. In the general Dutch population, a
person of 72.9 years lives 86 years in total, and a person
aged 79.6 years lives 88.5 years, on average.
With the SG method, only 38 % of the AMB+AMD
and only 49 % of the BAMD patients accepted risk of
death in exchange for cure. Both groups of elderly patients
with BVI had an overall (including all who accepted no
risk of death) mean SG utility value of approximately
0.999, in other words approximately a 0.1 % loss of SG
utility. Only two patients, aged over 80 years with BAMD,
accepted a risk of death of 1 in 50. In our previous study,
in 35-year-old persons with unilateral amblyopia, 37 % ac-
cepted risk of death [5]. Considering the fact that the SG
method implies risk of immediate death, it is understand-
able that most patients will not accept such a risk [10].
Similar to Brown et al. [11], we found that the TTO utility
value was lower than that from SG for the disability of
BVI. The disturbance that most affected the patients’ vis-
ual function was blurred vision in the center of the visual
field of the recently deteriorated eye which was in accord-
ance with the evaluation of their vision-related quality of
life by the VFQ-25. The day-to-day tasks that the patients
found difficult to perform were reading of normal and
small print, driving a car and writing; these activities de-
pend most on good central vision.
The study has two limitations. The first one was the
inability to derive utilities from patients in their pre-BVI
health state with the consequence that we could not
compare patients’ pre-BVI and BVI utility values. Sec-
ondly, the inclusion criterion of a decrease to Snellen
VA <0.5 could not be upheld in rare patients who were
found to have a major improvement in Snellen VA in
the amblyopic eye. Six other patients had slightly higher
acuity than threshold, namely Snellen VA of 0.6 in the
better eye.
As said, in an earlier study we found that patients with
unilateral visual impairment from persistent amblyopia,
approximately 35 years old, had 3.7 % loss of TTO utility
[8]. This may seem a small difference as compared to the
8 % loss in the 75-years-old patients with BVI in the
current study.
We think the moderate loss of utility caused by BVI in
75-years-old patients, compared with that caused by unilat-
eral persistent amblyopia –with good vision in the other
eye- in 35-years-old patients can be explained by adapta-
tion, avoidance of risk, comorbidity and a changed percept
of cure. Also, response shift does occur when eliciting util-
ities from old patients.
First, adaptation is an important coping mechanism of
patients to diminish the impact of chronic impairments,
described in clinical rehabilitation studies [12]. Adaptation
is age-dependent: elderly patients have had longer time
than adult patients of younger age to adapt to an identical
chronic disability, like visual function loss. Hence, the 75-
years-old AMB+AMD patients have adapted more than
the 35-years-old amblyopes to visual deterioration and its
resulting functional restrictions. In addition, hedonic adap-
tation could have occurred: The unilateral amblyopia and
unilateral AMD patients were, in first instance, shocked by
the deterioration in the better eye due to the AMD but
after a while would have accepted that and its
accompanying restrictions.
Secondly, patients older than 85 year did not want to
trade lifetime (see Fig. 1) or to accept risk of death, com-
patible with the phenomenon of risk avoidance at old
age [13]. Consistent with this observation is the correl-
ation between age and TTO utility in all patients (p <
0.001) that we found.
Thirdly, outcomes suggested a relation between TTO
value, VFQ-25A1 general health scale and VFQ-25A2
vision health. Patients who had low vision in both eyes
but still had a good general health, i.e. without comor-
bidity, seemed more willing to trade lifetime. This could,
however, not be confirmed statistically. Other studies
have also indicated that patients with worse general
health due to additional diseases like diabetes or heart
failure, are less willing to trade lifetime [14, 15].
Fourthly, healthy persons of approximately 37 years with
unilateral amblyopia have a higher demand of their nor-
mal functioning within their career than elderly patients
who are mostly retired. The younger adults have to be able
to drive a car and do their jobs or do the household; they
therefore have a higher percept of cure (“internal standard
of cure”) than the elderly patients with BVI.
Finally, some patients voiced a decreased relevance of
quality of life in general at old age, analogous to a re-
sponse shift, i.e. a re-conceptualization of quality of life in
general. Patients seemed to accept the forthcoming
deterioration of their health, including their vision, when
they were unwilling to give up lifetime [16]. The similar
phenomenon occurs also in the acceptance of pain among
elderly [17].
Conclusions
Elderly patients with BVI, caused by unilateral persistent
amblyopia and AMD or by bilateral AMD, had an ap-
proximately 8 % loss of TTO utility. This loss in elderly
with BVI differs little from the 3.7 % loss in 35-year-old
persons with unilateral amblyopia –with good vision in
the other eye- we found in a previous study, indicating a
lessened impact of visual impairment in senescence.
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